Industrial Hemp and Hemp Products Testing in Colorado Retail Marijuana Testing Facilities
On September 21, 2018, the Colorado Department of Revenue Marijuana Enforcement Division the (“MED”), the Colorado Department of Public Health and Environment (“CDPHE”), and the Colorado Department of Agriculture (“CDA”) issued a bulletin authorizing licensed Retail Marijuana Testing Facilities to test industrial hemp and industrial hemp products derived from hemp cultivated by a CDA registrant. The agencies issued the bulletin in an effort to propose amendments to current regulations and engage stakeholders in a discussion to address the scope and extent of industrial hemp and hemp products testing in Colorado.
Prior to the bulletin, Colorado law permitted MED licensed retail marijuana testing facilities to test industrial hemp, but only unprocessed plant material and only for testing potency. The proposed amendment to the rules would allow such testing facilities to test unprocessed industrial hemp plant material as well as industrial hemp products under certain circumstances. The agencies’ proposal authorizes testing on industrial hemp and industrial hemp products so long as the following requirements are met:
- The person submitting the sample for testing provides the retail marijuana testing facility with a CDA registration number indicating the origin of the material to be tested;
- The sample submitted for testing is tracked through the radio frequency-based inventory tracking system; and
- If the sample submitted for testing is a sample of a product to be used in the manufacture of an industrial hemp product, the manufacturer of the product possesses a CDPHE registration.
The agencies’ bulletin indicates the first stakeholder meeting to discuss these proposed changes is scheduled for Monday, October 1, 2018, from 9.30am to 12.30pm, at the Colorado Department of Agriculture, 305 Interlocken Parkway, Broomfield, CO 80021. Please contact McAllister Garfield should you have any questions about how these proposed changes will apply to your business, or if you would like the firm to represent your interests at stakeholder meetings on the issue.
Sincerely,
Garrett L. Davey, Esq.
Related Article
Psychedelic Therapy & Law Update – April 2026
President Trump to Issue Executive Order on Ibogaine President Trump will sign an executive order opening doors for more federal reserach on ibogaine, the naturally occuring psychedelic substance with indigenous roots in Africa. For more information, see this article by clicking here. Ibogaine has shown significant benefits for veterans suffering from war trauma, those suffering from […]
Psychedelic Therapy & Law Update – March 2026
Colorado starts the rulemaking process again for NMHA program changes DOR Natural Medicine Division is proposing several rules changes to the NMHA rules. These proposed changes include a significant increase in the cost of standard healing center licenses (from $6k to over $10k). Other proposed changes include adding an owner entity fee, prohibiting cultivator sampling […]
Psychedelic Therapy & Law Update – February 2026
Maryland and New Jersey moving toward creation of psilocybin programs The Maryland Task Force on Responsible Use of Natural Psychedelic Substances, in a report near the end of 2025 endorsed the creation of a regulated psilocybin program in the state. The recommendation still needs to be adopted by the Maryland legislature, but this is an […]